Twi Pharmaceuticals, Inc.
Twi Pharmaceuticals, Inc. (United States) holds 1 active US FDA Type II Drug Master File. No FDA recall, Warning Letter or Form 483 record is linked to it, which is not proof that none exists.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Twi Pharmaceuticals, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/twi-pharmaceuticals-inc
Overview
Twi Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Paramus, United States.
API / Drug Master Files
Twi Pharmaceuticals, Inc. holds 1 active (1 total) FDA Type II Drug Master File. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- NAPRELAN (NAPROXEN SODIUM) CONTROLLED-RELEASE TABLETS, 375MG, 500MG, 750MGActive2008-08-12
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Twi Pharmaceuticals, Inc. in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.
Is this Twi Pharmaceuticals, Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.